Navigation Links
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Date:7/22/2008

Two Regimens Including Lantus(R) and Apidra(R) Resulted in Significant Reductions in A1C in Patients with Type 2 Diabetes, Whatever the Algorithm

Used

BRIDGEWATER, N.J., July 22 /PRNewswire/ -- Results from the "Adjust to Target in Type 2 Diabetes: Comparison of a Simple Algorithm to Carbohydrate Counting for Adjustment of Mealtime Insulin Glulisine" study, were published in the American Diabetes Association's (ADA) medical journal, Diabetes Care. This study, using a basal-bolus insulin regimen with Lantus(R) (insulin glargine [rDNA origin] injection) once daily (basal insulin) and rapid-acting Apidra(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) demonstrated significant reductions in postprandial blood glucose and A1C using two different dosing algorithms.

The 24-week, multicenter, randomized, controlled study compared two algorithms for adjusting mealtime insulin (Apidra(R)) in 273 intent-to-treat patients with type 2 diabetes. Apidra(R) and Lantus(R) were adjusted weekly in both groups based on the previous week's self-monitored blood glucose (SMBG) results. One group, the "Simplified Algorithm" group, was provided set doses of Apidra(R) to take before each meal. The second group, the "Carbohydrate Counting" group, was provided an insulin-to-carbohydrate ratio to use for each meal and adjusted their Apidra(R) dose based on amount of carbohydrate consumed. After 24 weeks, the percentage of patients who achieved A1C<7 percent -- the ADA's recommended target for blood sugar control -- while following these two treatment algorithms were 73% and 69% (P=0.70), respectively.

Average A1C levels at week 24 were 6.70 in the Simplified Algorithm group and 6.54 percent in the Carb Counting group. The respective mean A1C changes from baseline to 24 weeks were -1.46 percent and -1.59 percent (P=.24). A1C <7.0 percent was achieved by 73 percent (Simplified Algorithm) and 69 percent (C
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009).... 6 Philips Respironics applauds t...Prevention (CDC) to raise awareness about an impor...iency. The CDC,s release of the first-ever governm... sleeplessness is a milestone in quantifying the s...e educator, industry leader and sleep therapy manu...
(Date:11/6/2009)...wswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CY...financial results for the second quarter ended Oct...2010 on Wednesday, November 18, 2009 at 5:00 PM ES...discuss those results on Thursday, November 19, 20... Quarter Results Conference Call Instructions ,...
(Date:11/6/2009)... , - Trial Will Compare N...eatment of Multi-Resistant Staphylococcus Aureus (...pharmaceutical company focused on the discovery an...rcome the significant global,problem of microbial ... oral,antibacterial NXL103 (flopristin/linopristin...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Florida Celebrates National Healthcare Quality Week 59698 1Florida Celebrates National Healthcare Quality Week 59698 2ULORIC 28R 29 28febuxostat 29 Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout 5547 1ULORIC 28R 29 28febuxostat 29 Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout 5547 2ULORIC 28R 29 28febuxostat 29 Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout 5547 3ULORIC 28R 29 28febuxostat 29 Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout 5547 4ULORIC 28R 29 28febuxostat 29 Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout 5547 5Video Games Can Play Havoc With Kids Joints 59696 1Video Games Can Play Havoc With Kids Joints 59696 2Video Games Can Play Havoc With Kids Joints 59696 3
...ated Foot & Ankle Specialists,today announced it i...etes,to participate in the MATRIX clinical trial. ... Excellarate, for the potential treatment of,patie...rate is an,investigational product designed to sti...trial is a randomized, double-blind safety and eff...
...Feb. 25 Joseph F. Finn, Jr.,CPA, the Assignee for...sult,of growing interest from prospective buyers, ... advancement of the company,s proprietary,benzoxaz...ates in,combination antibiotic therapy. Rifalazil ...ost of the interest for combination antibiotics ha...
Other Medicine Technology:ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics 2
(Date:11/9/2009)...y 5 percent of seniors have changed Medicare plans... service and improved coverage among biggest drive...nears , , Belleville, Il ...f seniors have changed their Medicare plan since b... report they are likely to or are considering swit...
(Date:11/9/2009)...wswire/ -- HUYA Bioscience International, a lead...tion, today announced a strategic partnership with...sity of China. The agreement is another in a serie... China,s leading research and development institut...nt and commercialization of novel biopharmaceutica...
(Date:11/9/2009)...young athletes are under increasing pressure to pl... University Health System study of 519 junior tenn...eases the risk of injury. Researchers who analyzed... junior competition found that players who special...rom tournaments for medical reasons, typically inj...
(Date:11/9/2009)...dy involving 2,453 women ages 18 to 68 found that ... a partner contributed to higher ratings of pleasu... have long been recommended to women to improve th...risk of vaginal tearing, yet strikingly little ava...nts or associated vaginal symptoms. , The study...
(Date:11/8/2009)...ewswire-USNewswire/ -- Jon O,Brien, president of C...t about the passage of HR 3962: ,, "Behavior i...lot about core values. We in the prochoice communi...come the struggles ordinary Americans have making ...fford basic healthcare or have to choose between m...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:Catholics for Choice Statement on Healthcare Reform Bill 2
...GTON, Sept. 23 Homeless veterans in 35,states, th...re assistance,thanks to Department of Veterans Aff...ity groups to create 1,526 beds for homeless veter... B. Peake.,"Our partnerships with community-based ...
...ome Foreclosures Displacing People and Dogs Alike,...eed Adopters, DENVER, Sept. 23 The housing crisi... unexpected group: dogs., Driven largely by the r... across the country say they are receiving dogs,ev...
...found giving it before radiation raised death risk...HealthDay News) -- Older men with early-stage pros...adiation seed implant therapy face a 20 percent gr... risks of death from any cause linked to androgen-...
... Program targets individuals u..., Irvine, Calif. (Vocus) S... to provide care to the most underserved populatio...diabetes management services to members of the Hea...
... Scribe announces a version of...ion and document archival technology for free , ...tember 23, 2008 -- Scribe Healthcare Technologies,... management, is now offering a version of its plat...
...ANA, Calif., Sept. 22 Grubb & Ellis,Healthcare RE...ma City,Medical Portfolio, comprising two medical ... and 5701 N. Portland, the buildings are situated ...ctive additions to the Grubb,& Ellis Healthcare RE...
Other Medicine News:Health News:VA Announces $36 Million in Grants for Homeless Programs 2Health News:VA Announces $36 Million in Grants for Homeless Programs 3Health News:VA Announces $36 Million in Grants for Homeless Programs 4Health News:VA Announces $36 Million in Grants for Homeless Programs 5Health News:VA Announces $36 Million in Grants for Homeless Programs 6Health News:VA Announces $36 Million in Grants for Homeless Programs 7Health News:VA Announces $36 Million in Grants for Homeless Programs 8Health News:VA Announces $36 Million in Grants for Homeless Programs 9Health News:VA Announces $36 Million in Grants for Homeless Programs 10Health News:This October, Bring Home a Shelter Dog for American Humane's Adopt-A-Dog Month(R) 2Health News:This October, Bring Home a Shelter Dog for American Humane's Adopt-A-Dog Month(R) 3Health News:Hormone Therapy Not Best for Older Prostate Cancer Patients 2Health News:Hormone Therapy Not Best for Older Prostate Cancer Patients 3Health News:LifeMasters Announces Agreement to Offer Disease Management Services to High-Risk Wisconsin Residents 2Health News:LifeMasters Announces Agreement to Offer Disease Management Services to High-Risk Wisconsin Residents 3Health News:Medical Dictation and Transcription Platform is Offered for Free 2Health News:Grubb & Ellis Healthcare REIT Acquires Oklahoma City Medical Portfolio 2Health News:Grubb & Ellis Healthcare REIT Acquires Oklahoma City Medical Portfolio 3
Ballard Neonatal and Pediatric Trach Care Elbow
Ballard Neonatal and Pediatric Trach Care Manifold
Portex® Blue Line ULTRA® Tracheostomy Tubes
...e Line ULTRA® Suctionaid® tracheostomy tub... removal of secretions from above the tracheostomy...uctionaid® tracheostomy tubes provide an addit...ons from above the tracheostomy tube cuff helping ...
Medicine Products: